Kallikrein Markers Can Reduce Unnecessary Prostate Biopsies
Author Information
Author(s): Andrew J Vickers, Angel M Cronin, Gunnar Aus, Carl-Gustav Pihl, Charlotte Becker, Kim Pettersson, Peter T Scardino, Jonas Hugosson, Hans Lilja
Primary Institution: Memorial Sloan-Kettering Cancer Center
Hypothesis
Can a multivariable model including kallikrein markers predict prostate biopsy outcomes in men with elevated PSA?
Conclusion
Using multiple kallikrein forms can help determine which men need a biopsy and which can continue screening without it.
Supporting Evidence
- Addition of kallikrein markers improved predictive accuracy significantly.
- Using a 20% risk threshold for biopsy could reduce unnecessary procedures by 57%.
- Only 31 low-grade and 3 high-grade cancers would be missed with the new model.
Takeaway
Doctors can use special blood tests to decide if men really need a prostate biopsy, which can help avoid unnecessary procedures.
Methodology
The study analyzed data from men undergoing biopsy in a prostate cancer screening trial, comparing predictive models with and without kallikrein markers.
Potential Biases
Potential verification bias due to not knowing the reason for some biopsies.
Limitations
The study's findings may not apply to men with previous PSA tests, and the accuracy of the model may decrease in such cases.
Participant Demographics
Men aged 50-66 years from Göteborg, Sweden.
Statistical Information
P-Value
p<0.0005
Confidence Interval
(0.804, 0.874)
Statistical Significance
p<0.0005
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website